CupidQ3 FY24

Cupid Q3 FY24 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹365.85P/E: 290.2Market Cap: ₹49.2K CrSector: Personal Products

Management growth scorecard

Revenue

Category 1

Margin

Category 1

Fundraise

Yes

Order

N/A

Capex

Yes

4 of 4 growth signals are positive — a strong management growth story.

Full analysis

Revenue guidance

Category 1
  • Post expansion, expected revenue to rise close to Rs. 400 crores (vs. earlier Rs. 320 crores).
  • EBITDA anticipated to exceed Rs. 100 crores after expansion completion.
  • Capacity to increase by 300 million male condoms by end of 2024, adding to existing 480 million capacity.
  • Female condom sales expected to significantly rise in Q4 FY24, contributing Rs. 21 crores.
  • Target to double sales from Rs. 160 crores in FY23 over next 3-4 years, factoring in acquisition and expansion.
  • Expansion supported by acquisition plans both in India and internationally to broaden product portfolio (condoms and IVD kits).
  • Retail presence growing; currently in ~1,000 outlets with focus on Northern India as test market; gradual scale-up planned.
  • Operating margins aimed to improve, EBITDA margins targeted above 35%, PAT margins over 25% as sales grow.

See what Cupid management said on margin guidance — free account, 30 seconds.

Fundraise plans

Yes
  • Cupid Limited is raising approximately Rs. 385 crores through issuance of non-convertible warrants primarily to FIIs (financial investors), resulting in around 15% equity dilution by adding about 22 lakh shares.
  • The fundraise is targeted mainly for strategic acquisitions outside India in the condom and IVD segments, as well as a small portion allocated for working capital.
  • The funds from the preferential issuance are expected to be received within 18 months.
  • No specific plan for additional debt fundraising was mentioned.
  • The company has sufficient funds in the balance sheet for ongoing expansion, including land acquisition and capacity increase.
  • No plan to raise funds through promoter dilution or to provide board seats to new investors, as none will hold more than 5%.

See what Cupid management said on order book — free account, 30 seconds.

Capex plans

Yes
  • Cupid Limited has acquired a land parcel and plans to commence new production lines within approximately two years as part of their expansion.
  • They are increasing male condom manufacturing capacity, aiming to add about 300 million units by the end of 2024, raising total capacity from 480 million units.
  • A significant portion of the recently raised Rs. 385-400 crore through share issuance is earmarked for strategic acquisitions, particularly outside India, targeting condom and IVD (In Vitro Diagnostics) businesses.
  • The company is focused on acquisitions that will expand product lines within the condom segment and potentially accelerate approvals for IVD products.
  • Apart from acquisitions, a small portion of funds will be used for working capital needs.
  • There are plans to bundle new products like deodorant sprays with existing offerings to enhance the product portfolio.
  • Overall, capital investments include capacity expansion at existing facilities and strategic acquisitions aimed at growth in domestic and international markets.

Track Cupid — get its next earnings analysis in your feed

How does Cupid rank vs peers in Personal Products?

Pro feature
ThisCupid
Rev 1Mar 1

How does Cupid rank in Personal Products?

Compare Cupid against every Personal Products company (Q3 FY24) on revenue, margins and earnings-call signals.

View Personal Products leaderboard →

Others in Personal Products this season

  • Anondita Medicare (Q2 FY27)

    Revenue (Standalone)** for H1 FY27: ₹5,786.31 Lakhs, up 21.43% YoY from ₹4,765.06 Lakhs in H1 FY26 . Key investor presentation takeaways from Anondita Medicare

  • Gillette India (Q2 FY27)

    Revenue from operations for the quarter ended 30th September 2026: ₹84,610 lakh (Page 3) . Key results statement takeaways from Gillette India Ltd's Q2 FY27 ear

  • Honasa Consumer (Q2 FY27)

    Younger brands, excluding The Derma Co., are growing healthily at 40%+ year-on-year, with the overall portfolio showing strong momentum across online and…

  • Emami (Q2 FY27)

    Volume growth for domestic business recorded 43% in Q2 and 26% on a like-to-like basis, indicating strong demand. Key concall takeaways from Emami Ltd's Q2…

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →